Heron Therapeutics, Inc. (HRTX)
USD 1.87
(-10.95%)
USD 1.87
(-10.95%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -110.55 Million USD | 17.81% |
| 2022 | -134.51 Million USD | 38.2% |
| 2021 | -217.66 Million USD | 3.02% |
| 2020 | -224.43 Million USD | -9.61% |
| 2019 | -204.74 Million USD | -14.49% |
| 2018 | -178.84 Million USD | 9.44% |
| 2017 | -197.48 Million USD | -14.06% |
| 2016 | -173.14 Million USD | -77.42% |
| 2015 | -97.59 Million USD | -27.79% |
| 2014 | -76.36 Million USD | -38.14% |
| 2013 | -55.28 Million USD | -136.78% |
| 2012 | -23.34 Million USD | -97.63% |
| 2011 | -11.81 Million USD | -60.82% |
| 2010 | -7.34 Million USD | 26.75% |
| 2009 | -10.02 Million USD | 56.64% |
| 2008 | -23.12 Million USD | -14.69% |
| 2007 | -20.16 Million USD | -482.89% |
| 2006 | 5.26 Million USD | 164.14% |
| 2005 | -8.21 Million USD | 10.96% |
| 2004 | -9.22 Million USD | -111.35% |
| 2003 | -4.36 Million USD | -15.48% |
| 2002 | -3.77 Million USD | -50.3% |
| 2001 | -2.51 Million USD | -129.39% |
| 2000 | 8.55 Million USD | 256.35% |
| 1999 | 2.4 Million USD | 26.32% |
| 1998 | 1.9 Million USD | 371.43% |
| 1997 | -700 Thousand USD | 92.55% |
| 1996 | -9.4 Million USD | 0.0% |
| 1995 | -9.4 Million USD | 4.08% |
| 1994 | -9.8 Million USD | 1.01% |
| 1993 | -9.9 Million USD | -76.79% |
| 1992 | -5.6 Million USD | -30.23% |
| 1991 | -4.3 Million USD | -10.26% |
| 1990 | -3.9 Million USD | 13.33% |
| 1989 | -4.5 Million USD | 10.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -3.16 Million USD | 70.53% |
| 2024 Q2 | -9.23 Million USD | -192.25% |
| 2023 Q3 | -25 Million USD | 40.54% |
| 2023 Q4 | -10.72 Million USD | 57.12% |
| 2023 Q2 | -42.05 Million USD | -29.52% |
| 2023 FY | -110.55 Million USD | 17.81% |
| 2023 Q1 | -32.47 Million USD | -19.35% |
| 2022 FY | -134.51 Million USD | 38.2% |
| 2022 Q1 | -64.85 Million USD | -18.68% |
| 2022 Q2 | -63.22 Million USD | 2.52% |
| 2022 Q3 | -41.93 Million USD | 33.67% |
| 2022 Q4 | -27.2 Million USD | 35.11% |
| 2021 Q2 | -61.01 Million USD | -15.97% |
| 2021 Q1 | -52.61 Million USD | 15.52% |
| 2021 Q3 | -52.4 Million USD | 14.11% |
| 2021 Q4 | -54.64 Million USD | -4.27% |
| 2021 FY | -217.66 Million USD | 3.02% |
| 2020 Q4 | -62.28 Million USD | -6.96% |
| 2020 Q3 | -58.22 Million USD | -5.5% |
| 2020 FY | -224.43 Million USD | -9.61% |
| 2020 Q1 | -51.57 Million USD | 10.95% |
| 2020 Q2 | -55.19 Million USD | -7.0% |
| 2019 Q3 | -33.59 Million USD | 33.11% |
| 2019 Q2 | -50.22 Million USD | 20.3% |
| 2019 Q1 | -63.01 Million USD | -27.15% |
| 2019 FY | -204.74 Million USD | -14.49% |
| 2019 Q4 | -57.92 Million USD | -72.41% |
| 2018 Q4 | -49.55 Million USD | -29.24% |
| 2018 Q2 | -38.67 Million USD | 26.01% |
| 2018 FY | -178.84 Million USD | 9.44% |
| 2018 Q1 | -52.26 Million USD | 16.36% |
| 2018 Q3 | -38.34 Million USD | 0.84% |
| 2017 Q4 | -62.49 Million USD | -49.26% |
| 2017 Q1 | -50.32 Million USD | -4.93% |
| 2017 Q2 | -42.79 Million USD | 14.96% |
| 2017 FY | -197.48 Million USD | -14.06% |
| 2017 Q3 | -41.86 Million USD | 2.18% |
| 2016 Q3 | -48.5 Million USD | -12.22% |
| 2016 FY | -173.14 Million USD | -77.42% |
| 2016 Q1 | -33.44 Million USD | -7.05% |
| 2016 Q4 | -47.96 Million USD | 1.13% |
| 2016 Q2 | -43.22 Million USD | -29.25% |
| 2015 Q4 | -31.24 Million USD | -37.8% |
| 2015 FY | -97.59 Million USD | -27.79% |
| 2015 Q2 | -23.1 Million USD | -12.33% |
| 2015 Q1 | -20.57 Million USD | 0.26% |
| 2015 Q3 | -22.67 Million USD | 1.88% |
| 2014 FY | -76.36 Million USD | -38.14% |
| 2014 Q4 | -20.62 Million USD | -7.45% |
| 2014 Q3 | -19.19 Million USD | -0.96% |
| 2014 Q2 | -19.01 Million USD | -8.4% |
| 2014 Q1 | -17.53 Million USD | -24.88% |
| 2013 FY | -55.28 Million USD | -136.78% |
| 2013 Q1 | -12.95 Million USD | -67.42% |
| 2013 Q4 | -14.04 Million USD | -9.1% |
| 2013 Q2 | -15.41 Million USD | -18.99% |
| 2013 Q3 | -12.87 Million USD | 16.48% |
| 2012 Q4 | -7.73 Million USD | -26.4% |
| 2012 FY | -23.34 Million USD | -97.63% |
| 2012 Q3 | -6.12 Million USD | -33.97% |
| 2012 Q2 | -4.56 Million USD | 7.15% |
| 2012 Q1 | -4.92 Million USD | -15.49% |
| 2011 Q1 | -1.41 Million USD | 11.09% |
| 2011 Q4 | -4.26 Million USD | -1.4% |
| 2011 Q2 | -1.93 Million USD | -36.15% |
| 2011 Q3 | -4.2 Million USD | -117.49% |
| 2011 FY | -11.81 Million USD | -60.82% |
| 2010 Q1 | -495 Thousand USD | 74.12% |
| 2010 Q2 | -3.58 Million USD | -623.84% |
| 2010 Q3 | -1.67 Million USD | 53.34% |
| 2010 Q4 | -1.59 Million USD | 4.55% |
| 2010 FY | -7.34 Million USD | 26.75% |
| 2009 Q1 | -2.96 Million USD | 24.99% |
| 2009 Q3 | -1.21 Million USD | 69.2% |
| 2009 Q4 | -1.91 Million USD | -57.58% |
| 2009 FY | -10.02 Million USD | 56.64% |
| 2009 Q2 | -3.94 Million USD | -33.14% |
| 2008 Q4 | -3.94 Million USD | 36.41% |
| 2008 Q1 | -6.84 Million USD | 11.13% |
| 2008 Q2 | -6.13 Million USD | 10.43% |
| 2008 FY | -23.12 Million USD | -14.69% |
| 2008 Q3 | -6.2 Million USD | -1.22% |
| 2007 Q2 | -1.77 Million USD | 70.4% |
| 2007 Q1 | -6 Million USD | -5.91% |
| 2007 Q3 | -4.68 Million USD | -163.8% |
| 2007 FY | -20.16 Million USD | -482.89% |
| 2007 Q4 | -7.7 Million USD | -64.38% |
| 2006 Q3 | -3.81 Million USD | 16.11% |
| 2006 Q1 | 19.29 Million USD | 841.41% |
| 2006 FY | 5.26 Million USD | 164.14% |
| 2006 Q2 | -4.55 Million USD | -123.58% |
| 2006 Q4 | -5.66 Million USD | -48.44% |
| 2005 Q2 | -2.6 Million USD | -107.64% |
| 2005 Q4 | -2.6 Million USD | -49.25% |
| 2005 Q3 | -1.74 Million USD | 33.13% |
| 2005 FY | -8.21 Million USD | 10.96% |
| 2005 Q1 | -1.25 Million USD | 44.35% |
| 2004 FY | -9.22 Million USD | -111.35% |
| 2004 Q1 | -2.59 Million USD | -88.61% |
| 2004 Q4 | -2.25 Million USD | -17.49% |
| 2004 Q3 | -1.92 Million USD | 21.4% |
| 2004 Q2 | -2.44 Million USD | 5.96% |
| 2003 FY | -4.36 Million USD | -15.48% |
| 2003 Q3 | -1.05 Million USD | 46.02% |
| 2003 Q4 | -1.37 Million USD | -30.25% |
| 2003 Q2 | -1.96 Million USD | -5864.71% |
| 2003 Q1 | 34 Thousand USD | 114.98% |
| 2002 Q3 | -1.05 Million USD | 29.54% |
| 2002 FY | -3.77 Million USD | -50.3% |
| 2002 Q4 | -227 Thousand USD | 78.42% |
| 2002 Q1 | -1 Million USD | 40.39% |
| 2002 Q2 | -1.49 Million USD | -48.54% |
| 2001 Q4 | -1.68 Million USD | -213.08% |
| 2001 FY | -2.51 Million USD | -129.39% |
| 2001 Q1 | -1.12 Million USD | 29.58% |
| 2001 Q2 | -1.19 Million USD | -6.81% |
| 2001 Q3 | 1.49 Million USD | 224.53% |
| 2000 FY | 8.55 Million USD | 256.35% |
| 2000 Q3 | 10.55 Million USD | 1766.1% |
| 2000 Q2 | -633.68 Thousand USD | -387.65% |
| 2000 Q4 | -1.59 Million USD | -115.08% |
| 2000 Q1 | 220.29 Thousand USD | -84.26% |
| 1999 Q1 | 300 Thousand USD | -72.73% |
| 1999 FY | 2.4 Million USD | 26.32% |
| 1999 Q3 | 500 Thousand USD | 66.67% |
| 1999 Q2 | 300 Thousand USD | 0.0% |
| 1999 Q4 | 1.4 Million USD | 180.0% |
| 1998 Q1 | - USD | 100.0% |
| 1998 FY | 1.9 Million USD | 371.43% |
| 1998 Q2 | 200 Thousand USD | 0.0% |
| 1998 Q4 | 1.1 Million USD | 120.0% |
| 1998 Q3 | 500 Thousand USD | 150.0% |
| 1997 FY | -700 Thousand USD | 92.55% |
| 1997 Q2 | -600 Thousand USD | -250.0% |
| 1997 Q4 | -100 Thousand USD | 75.0% |
| 1997 Q3 | -400 Thousand USD | 33.33% |
| 1997 Q1 | 400 Thousand USD | 112.5% |
| 1996 FY | -9.4 Million USD | 0.0% |
| 1996 Q1 | -2 Million USD | 55.56% |
| 1996 Q3 | -2.1 Million USD | 0.0% |
| 1996 Q2 | -2.1 Million USD | -5.0% |
| 1996 Q4 | -3.2 Million USD | -52.38% |
| 1995 Q2 | -2 Million USD | -122.22% |
| 1995 Q4 | -4.5 Million USD | -125.0% |
| 1995 Q3 | -2 Million USD | 0.0% |
| 1995 FY | -9.4 Million USD | 4.08% |
| 1995 Q1 | -900 Thousand USD | 64.0% |
| 1994 Q2 | -2.7 Million USD | -50.0% |
| 1994 Q1 | -1.8 Million USD | 41.94% |
| 1994 FY | -9.8 Million USD | 1.01% |
| 1994 Q3 | -2.7 Million USD | 0.0% |
| 1994 Q4 | -2.5 Million USD | 7.41% |
| 1993 Q3 | -2.5 Million USD | 10.71% |
| 1993 FY | -9.9 Million USD | -76.79% |
| 1993 Q4 | -3.1 Million USD | -24.0% |
| 1993 Q1 | -1.8 Million USD | 0.0% |
| 1993 Q2 | -2.8 Million USD | -55.56% |
| 1992 Q1 | -1.9 Million USD | -26.67% |
| 1992 FY | -5.6 Million USD | -30.23% |
| 1992 Q3 | -900 Thousand USD | 10.0% |
| 1992 Q4 | -1.8 Million USD | -100.0% |
| 1992 Q2 | -1 Million USD | 47.37% |
| 1991 FY | -4.3 Million USD | -10.26% |
| 1991 Q4 | -1.5 Million USD | -25.0% |
| 1991 Q1 | -1.1 Million USD | -83.33% |
| 1991 Q2 | -500 Thousand USD | 54.55% |
| 1991 Q3 | -1.2 Million USD | -140.0% |
| 1990 FY | -3.9 Million USD | 13.33% |
| 1990 Q1 | -900 Thousand USD | 18.18% |
| 1990 Q3 | -1.2 Million USD | -9.09% |
| 1990 Q4 | -600 Thousand USD | 50.0% |
| 1990 Q2 | -1.1 Million USD | -22.22% |
| 1989 Q1 | - USD | 0.0% |
| 1989 Q3 | -900 Thousand USD | 0.0% |
| 1989 Q4 | -1.1 Million USD | -22.22% |
| 1989 FY | -4.5 Million USD | 10.0% |
| 1989 Q2 | -900 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AbCellera Biologics Inc. | -146.39 Million USD | 24.481% |
| Alkermes plc | 355.75 Million USD | 131.077% |
| Agenus Inc. | -245.76 Million USD | 55.014% |
| Aptorum Group Limited | -2.82 Million USD | -3814.082% |
| Ardelyx, Inc. | -66.06 Million USD | -67.344% |
| Dyadic International, Inc. | -6.79 Million USD | -1526.954% |
| Eton Pharmaceuticals, Inc. | -936 Thousand USD | -11711.859% |
| Lantern Pharma Inc. | -15.96 Million USD | -592.659% |
| Inhibikase Therapeutics, Inc. | -19.02 Million USD | -481.006% |
| Novavax, Inc. | -545.06 Million USD | 79.716% |
| Janux Therapeutics, Inc. | -58.29 Million USD | -89.661% |
| Pyxis Oncology, Inc. | -73.79 Million USD | -49.829% |
| TransCode Therapeutics, Inc. | -18.54 Million USD | -496.131% |
| Ocuphire Pharma, Inc. | -9.98 Million USD | -1007.14% |
| Outlook Therapeutics, Inc. | -58.98 Million USD | -87.443% |
| Madrigal Pharmaceuticals, Inc. | -373.63 Million USD | 70.409% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | -354.241% |
| SELLAS Life Sciences Group, Inc. | -37.34 Million USD | -196.087% |
| Syros Pharmaceuticals, Inc. | -164.57 Million USD | 32.821% |
| Barinthus Biotherapeutics plc | -73.34 Million USD | -50.734% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | -444.867% |
| Xeris Biopharma Holdings, Inc. | -62.25 Million USD | -77.591% |
| Clearside Biomedical, Inc. | -32.48 Million USD | -240.339% |
| C4 Therapeutics, Inc. | -132.49 Million USD | 16.555% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 74.887% |
| AlloVir, Inc. | -190.41 Million USD | 41.939% |
| Arrowhead Pharmaceuticals, Inc. | -205.27 Million USD | 46.141% |
| VYNE Therapeutics Inc. | -28.45 Million USD | -288.581% |
| Bicycle Therapeutics plc | -180.66 Million USD | 38.804% |
| BioXcel Therapeutics, Inc. | -179.05 Million USD | 38.253% |
| ChromaDex Corporation | -4.93 Million USD | -2138.943% |
| Chimerix, Inc. | -82.09 Million USD | -34.672% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -147.872% |
| Caribou Biosciences, Inc. | -102.07 Million USD | -8.317% |
| CRISPR Therapeutics AG | -153.61 Million USD | 28.026% |
| Precision BioSciences, Inc. | -61.31 Million USD | -80.301% |
| Fate Therapeutics, Inc. | -160.92 Million USD | 31.299% |
| Fortress Biotech, Inc. | -60.63 Million USD | -82.329% |
| Fortress Biotech, Inc. | -60.63 Million USD | -82.329% |
| HOOKIPA Pharma Inc. | -81.58 Million USD | -35.522% |
| ImmuCell Corporation | -5.77 Million USD | -1814.575% |
| IDEAYA Biosciences, Inc. | -112.96 Million USD | 2.126% |
| Immix Biopharma, Inc. | -15.42 Million USD | -616.703% |
| Incyte Corporation | 597.59 Million USD | 118.501% |
| Innoviva, Inc. | 179.72 Million USD | 161.517% |
| IO Biotech, Inc. | -86.08 Million USD | -28.433% |
| Jaguar Health, Inc. | -41.3 Million USD | -167.697% |
| Keros Therapeutics, Inc. | -152.99 Million USD | 27.735% |
| Ligand Pharmaceuticals Incorporated | 52.15 Million USD | 311.986% |
| ContextLogic Inc. | -317 Million USD | 65.123% |
| MiMedx Group, Inc. | 67.43 Million USD | 263.939% |
| MEI Pharma, Inc. | 17.77 Million USD | 721.887% |
| NextCure, Inc. | -62.72 Million USD | -76.265% |
| Onconetix, Inc. | -37.4 Million USD | -195.536% |
| Oncternal Therapeutics, Inc. | -39.47 Million USD | -180.045% |
| Opthea Limited | -220.24 Million USD | 49.801% |
| Psyence Biomedical Ltd. | -51.15 Million USD | -116.108% |
| Vaxcyte, Inc. | -402.26 Million USD | 72.516% |
| PDS Biotechnology Corporation | -42.94 Million USD | -157.46% |
| Precigen, Inc. | -95.9 Million USD | -15.281% |
| Pharming Group N.V. | -10.54 Million USD | -948.151% |
| Phathom Pharmaceuticals, Inc. | -201.59 Million USD | 45.157% |
| Pieris Pharmaceuticals, Inc. | -24.54 Million USD | -350.471% |
| PureTech Health plc | -65.69 Million USD | -68.286% |
| Rigel Pharmaceuticals, Inc. | -25.09 Million USD | -340.632% |
| Avidity Biosciences, Inc. | -212.22 Million USD | 47.904% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | -354.241% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 57.12% |
| Sol-Gel Technologies Ltd. | -27.23 Million USD | -305.9% |
| Acelyrin, Inc. | -381.64 Million USD | 71.031% |
| Salarius Pharmaceuticals, Inc. | -12.54 Thousand USD | -881361.632% |
| Summit Therapeutics Inc. | -614.92 Million USD | 82.021% |
| Sensei Biotherapeutics, Inc. | -34.1 Million USD | -224.21% |
| Senti Biosciences, Inc. | -92.91 Million USD | -18.984% |
| Stoke Therapeutics, Inc. | -104.69 Million USD | -5.597% |
| Elevation Oncology, Inc. | -45.7 Million USD | -141.902% |
| Alaunos Therapeutics, Inc. | -35.14 Million USD | -214.624% |
| Telomir Pharmaceuticals, Inc. Common Stock | -13.07 Million USD | -745.778% |
| Entrada Therapeutics, Inc. | -6.68 Million USD | -1553.837% |
| VistaGen Therapeutics, Inc. | -29.36 Million USD | -276.538% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | -1200.541% |
| Wave Life Sciences Ltd. | -57.51 Million USD | -92.233% |
| Seer, Inc. | -86.27 Million USD | -28.144% |
| Verrica Pharmaceuticals Inc. | -66.99 Million USD | -65.026% |
| Aadi Bioscience, Inc. | -65.76 Million USD | -68.112% |
| ESSA Pharma Inc. | -26.58 Million USD | -315.911% |
| GlycoMimetics, Inc. | -36.89 Million USD | -199.623% |
| GT Biopharma, Inc. | -7.59 Million USD | -1355.298% |
| Inhibrx Biosciences, Inc. | -241.36 Million USD | 54.194% |
| Akebia Therapeutics, Inc. | -51.92 Million USD | -112.921% |
| Catalyst Pharmaceuticals, Inc. | 71.41 Million USD | 254.823% |
| Longboard Pharmaceuticals, Inc. | -54.42 Million USD | -103.151% |
| Orchestra BioMed Holdings, Inc. | -49.12 Million USD | -125.079% |
| Alzamend Neuro, Inc. | -9.94 Million USD | -1011.397% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 80.7% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | -2981.355% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | -116.536% |
| Rocket Pharmaceuticals, Inc. | -245.59 Million USD | 54.983% |
| Aptose Biosciences Inc. | -51.2 Million USD | -115.906% |
| ZyVersa Therapeutics, Inc. | -98.29 Million USD | -12.473% |
| Soligenix, Inc. | -6.14 Million USD | -1700.421% |
| Century Therapeutics, Inc. | -136.67 Million USD | 19.107% |
| Kura Oncology, Inc. | -152.63 Million USD | 27.565% |
| TScan Therapeutics, Inc. | -89.21 Million USD | -23.92% |
| Intensity Therapeutics, Inc. | -10.53 Million USD | -949.146% |
| Ocean Biomedical, Inc. | 565.47 Thousand USD | 19651.7% |
| CytomX Therapeutics, Inc. | -569 Thousand USD | -19330.404% |
| Autolus Therapeutics plc | -208.38 Million USD | 46.944% |
| Mineralys Therapeutics, Inc. | -71.89 Million USD | -53.772% |
| EyePoint Pharmaceuticals, Inc. | -70.79 Million USD | -56.168% |
| Eterna Therapeutics Inc. | -21.66 Million USD | -410.241% |
| Adaptive Biotechnologies Corporation | -225.25 Million USD | 50.917% |
| GRI Bio, Inc. | -13.03 Million USD | -748.04% |
| Xenetic Biosciences, Inc. | -4.13 Million USD | -2574.009% |
| Tenaya Therapeutics, Inc. | -124.08 Million USD | 10.9% |
| IGM Biosciences, Inc. | -246.41 Million USD | 55.133% |
| INmune Bio, Inc. | -30 Million USD | -268.432% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | -162.027% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | -592.654% |
| Entero Therapeutics, Inc. | -15.79 Million USD | -599.963% |
| Milestone Pharmaceuticals Inc. | -59.68 Million USD | -85.237% |
| X4 Pharmaceuticals, Inc. | -101.16 Million USD | -9.284% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 59.961% |
| Coherus BioSciences, Inc. | -237.89 Million USD | 53.526% |
| Verastem, Inc. | -87.36 Million USD | -26.545% |
| Abeona Therapeutics Inc. | -54.18 Million USD | -104.029% |
| Pliant Therapeutics, Inc. | -161.33 Million USD | 31.473% |
| Tonix Pharmaceuticals Holding Corp. | -116.65 Million USD | 5.228% |
| Histogen Inc. | -10.62 Million USD | -940.947% |
| Aprea Therapeutics, Inc. | -14.28 Million USD | -673.857% |
| Surrozen, Inc. | -43.04 Million USD | -156.863% |
| Organovo Holdings, Inc. | -14.67 Million USD | -653.589% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | -2073.351% |
| Ovid Therapeutics Inc. | -52.33 Million USD | -111.237% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | -337.632% |
| CASI Pharmaceuticals, Inc. | -26.93 Million USD | -310.42% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.35 Million USD | -1222.937% |
| Centessa Pharmaceuticals plc | -151.08 Million USD | 26.823% |
| Hepion Pharmaceuticals, Inc. | -48.92 Million USD | -125.972% |
| Arcturus Therapeutics Holdings Inc. | -29.72 Million USD | -271.939% |
| BioRestorative Therapies, Inc. | -10.41 Million USD | -961.261% |
| Apollomics, Inc. | -172.6 Million USD | 35.945% |
| Amarin Corporation plc | -59.11 Million USD | -87.033% |
| Mesoblast Limited | -87.95 Million USD | -25.698% |
| Turnstone Biologics Corp. | -55.2 Million USD | -100.288% |
| Kymera Therapeutics, Inc. | -146.96 Million USD | 24.77% |
| Synaptogenix, Inc. | -6.03 Million USD | -1730.901% |
| Tiziana Life Sciences Ltd | -16.2 Million USD | -582.126% |
| Aurinia Pharmaceuticals Inc. | -78.02 Million USD | -41.706% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -2207.415% |
| Monopar Therapeutics Inc. | -8.4 Million USD | -1215.835% |
| Exelixis, Inc. | 207.76 Million USD | 153.213% |
| Better Therapeutics, Inc. | -39.76 Million USD | -178.066% |
| Nurix Therapeutics, Inc. | -143.94 Million USD | 23.195% |
| Apellis Pharmaceuticals, Inc. | -528.62 Million USD | 79.086% |
| NLS Pharmaceutics AG | -12.17 Million USD | -808.304% |
| Dermata Therapeutics, Inc. | -7.79 Million USD | -1318.389% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | -259.553% |
| Gritstone bio, Inc. | -138.49 Million USD | 20.168% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | -71.502% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | -2664.01% |
| Avid Bioservices, Inc. | -140.75 Million USD | 21.452% |
| Insmed Incorporated | -749.56 Million USD | 85.25% |
| Virpax Pharmaceuticals, Inc. | -15.18 Million USD | -627.864% |
| MediWound Ltd. | -6.71 Million USD | -1546.203% |
| OmniAb, Inc. | -50.61 Million USD | -118.414% |
| Alector, Inc. | -130.39 Million USD | 15.21% |
| Seres Therapeutics, Inc. | -113.72 Million USD | 2.783% |
| Checkpoint Therapeutics, Inc. | -51.84 Million USD | -113.241% |
| Zai Lab Limited | -334.62 Million USD | 66.96% |
| Revance Therapeutics, Inc. | -323.98 Million USD | 65.875% |
| Aura Biosciences, Inc. | -76.4 Million USD | -44.696% |
| Lyell Immunopharma, Inc. | -234.63 Million USD | 52.88% |
| Immunic, Inc. | -93.61 Million USD | -18.103% |
| Tarsus Pharmaceuticals, Inc. | -135.89 Million USD | 18.643% |
| Veracyte, Inc. | -74.4 Million USD | -48.593% |
| InMed Pharmaceuticals Inc. | -7.67 Million USD | -1340.405% |
| FibroGen, Inc. | -284.23 Million USD | 61.103% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | -321.466% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | -1478.988% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.83 Million USD | -487.059% |
| Jazz Pharmaceuticals plc | 414.83 Million USD | 126.652% |
| Cyclacel Pharmaceuticals, Inc. | -22.55 Million USD | -390.175% |
| Amylyx Pharmaceuticals, Inc. | 49.27 Million USD | 324.39% |
| TG Therapeutics, Inc. | 12.67 Million USD | 972.467% |
| Galecto, Inc. | -38.34 Million USD | -188.297% |
| Calithera Biosciences, Inc. | -18.86 Million USD | -486.022% |
| Fortrea Holdings Inc. | -3.4 Million USD | -3151.735% |
| KalVista Pharmaceuticals, Inc. | -126.64 Million USD | 12.701% |
| Aptevo Therapeutics Inc. | -17.41 Million USD | -534.995% |
| XBiotech Inc. | -24.55 Million USD | -350.214% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | -71.502% |
| Lyra Therapeutics, Inc. | -62.68 Million USD | -76.386% |
| Foghorn Therapeutics Inc. | -98.42 Million USD | -12.327% |
| Y-mAbs Therapeutics, Inc. | -21.42 Million USD | -415.98% |
| Theravance Biopharma, Inc. | -55.19 Million USD | -100.313% |
| Ultragenyx Pharmaceutical Inc. | -606.63 Million USD | 81.775% |
| Metagenomi, Inc. Common Stock | -68.25 Million USD | -61.979% |
| Vaxxinity, Inc. | -56.93 Thousand USD | -194088.007% |
| BioCryst Pharmaceuticals, Inc. | -226.53 Million USD | 51.196% |
| Gain Therapeutics, Inc. | -22.26 Million USD | -396.503% |
| Cartesian Therapeutics, Inc. | -219.71 Million USD | 49.68% |
| NexImmune, Inc. | -32.34 Million USD | -241.818% |
| Creative Medical Technology Holdings, Inc. | -5.28 Million USD | -1991.317% |
| Marker Therapeutics, Inc. | -14.04 Million USD | -687.127% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 102.796% |
| Chemomab Therapeutics Ltd. | -24.22 Million USD | -356.459% |
| Scopus BioPharma Inc. | -11.6 Million USD | -852.288% |
| RAPT Therapeutics, Inc. | -116.79 Million USD | 5.342% |
| Ainos, Inc. | -13.77 Million USD | -702.866% |
| Pluri Inc. | -20.88 Million USD | -429.294% |
| Prothena Corporation plc | -147.02 Million USD | 24.804% |
| Adaptimmune Therapeutics plc | -113.87 Million USD | 2.909% |
| Celularity Inc. | -196.29 Million USD | 43.677% |
| Rallybio Corporation | -74.56 Million USD | -48.274% |
| Cue Biopharma, Inc. | -50.73 Million USD | -117.923% |
| MeiraGTx Holdings plc | -84.02 Million USD | -31.576% |
| Omeros Corporation | -117.81 Million USD | 6.157% |
| Humacyte, Inc. | -110.77 Million USD | 0.196% |
| Immunocore Holdings plc | -55.28 Million USD | -99.973% |
| Cocrystal Pharma, Inc. | -17.98 Million USD | -514.763% |
| Cidara Therapeutics, Inc. | -22.93 Million USD | -382.138% |
| Blueprint Medicines Corporation | -506.98 Million USD | 78.193% |
| CalciMedica, Inc. | -34.35 Million USD | -221.795% |
| Cabaletta Bio, Inc. | -67.67 Million USD | -63.368% |
| Marinus Pharmaceuticals, Inc. | -141.4 Million USD | 21.814% |
| Scholar Rock Holding Corporation | -165.78 Million USD | 33.313% |
| Sana Biotechnology, Inc. | -283.25 Million USD | 60.968% |
| Pulmatrix, Inc. | -14.12 Million USD | -682.94% |
| Elicio Therapeutics, Inc. | -35.19 Million USD | -214.133% |
| Vigil Neuroscience, Inc. | -82.63 Million USD | -33.787% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 77.024% |
| Adlai Nortye Ltd. American Depositary Shares | -104.87 Million USD | -5.424% |
| Cytokinetics, Incorporated | -526.24 Million USD | 78.991% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | -206.555% |
| Nutriband Inc. | -5.48 Million USD | -1915.546% |
| Protara Therapeutics, Inc. | -40.42 Million USD | -173.525% |
| Vor Biopharma Inc. | -117.86 Million USD | 6.197% |
| Roivant Sciences Ltd. | 4.34 Billion USD | 102.542% |
| Evogene Ltd. | -23.87 Million USD | -362.997% |
| ProKidney Corp. | -35.46 Million USD | -211.715% |
| Applied Therapeutics, Inc. | -119.76 Million USD | 7.685% |
| Hoth Therapeutics, Inc. | -7.84 Million USD | -1309.222% |
| BridgeBio Pharma, Inc. | -643.2 Million USD | 82.811% |
| CorMedix Inc. | -46.33 Million USD | -138.586% |
| BioLineRx Ltd. | -60.61 Million USD | -82.398% |
| Tango Therapeutics, Inc. | -101.74 Million USD | -8.664% |
| Galectin Therapeutics Inc. | -41.06 Million USD | -169.223% |
| Atai Life Sciences N.V. | -40.22 Million USD | -174.858% |
| Renovaro Biosciences Inc. | -80.65 Million USD | -37.085% |
| Aerovate Therapeutics, Inc. | -75.52 Million USD | -46.395% |
| Zentalis Pharmaceuticals, Inc. | -292.19 Million USD | 62.162% |
| Sagimet Biosciences Inc. | -27.87 Million USD | -296.61% |
| MediciNova, Inc. | -8.57 Million USD | -1189.842% |
| Praxis Precision Medicines, Inc. | -123.27 Million USD | 10.317% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | -1219.818% |
| GeoVax Labs, Inc. | -25.96 Million USD | -325.771% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 53.787% |
| Biomea Fusion, Inc. | -117.25 Million USD | 5.711% |
| PTC Therapeutics, Inc. | -626.6 Million USD | 82.356% |
| Mereo BioPharma Group plc | -29.46 Million USD | -275.209% |
| Cullinan Oncology, Inc. | -153.16 Million USD | 27.816% |
| Syndax Pharmaceuticals, Inc. | -209.36 Million USD | 47.192% |
| Absci Corporation | -110.56 Million USD | 0.006% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | -266.697% |
| 4D Molecular Therapeutics, Inc. | -100.83 Million USD | -9.641% |
| Dyne Therapeutics, Inc. | -235.93 Million USD | 53.14% |
| Kiniksa Pharmaceuticals, Ltd. | 14.08 Million USD | 884.997% |
| Ventyx Biosciences, Inc. | -192.96 Million USD | 42.704% |
| Allakos Inc. | -185.7 Million USD | 40.464% |
| Imunon, Inc. | -19.51 Million USD | -466.534% |
| Fulcrum Therapeutics, Inc. | -97.33 Million USD | -13.586% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 204.163% |
| BioAtla, Inc. | -123.46 Million USD | 10.451% |
| NLS Pharmaceutics AG | -12.17 Million USD | -808.304% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | -587.641% |
| Allogene Therapeutics, Inc. | -327.26 Million USD | 66.217% |
| Larimar Therapeutics, Inc. | -36.94 Million USD | -199.221% |
| XOMA Corporation | -40.83 Million USD | -170.772% |
| Kezar Life Sciences, Inc. | -101.87 Million USD | -8.529% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 6.712% |
| aTyr Pharma, Inc. | -50.38 Million USD | -119.411% |
| Aligos Therapeutics, Inc. | -87.67 Million USD | -26.095% |
| Akero Therapeutics, Inc. | -151.75 Million USD | 27.148% |
| Viridian Therapeutics, Inc. | -237.73 Million USD | 53.495% |
| Eliem Therapeutics, Inc. | -35.11 Million USD | -214.812% |
| EyeGate Pharmaceuticals, Inc. | -8.09 Million USD | -1266.285% |
| Akari Therapeutics, Plc | -10 Million USD | -1004.706% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | -164116.859% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 139.262% |
| Lexaria Bioscience Corp. | -6.66 Million USD | -1558.825% |
| UroGen Pharma Ltd. | -102.24 Million USD | -8.133% |
| Sutro Biopharma, Inc. | -106.79 Million USD | -3.526% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | -1321.581% |
| Orgenesis Inc. | -55.36 Million USD | -99.706% |
| Entera Bio Ltd. | -8.88 Million USD | -1143.773% |
| GH Research PLC | -35.58 Million USD | -210.672% |
| Lisata Therapeutics, Inc. | -20.84 Million USD | -430.513% |
| Reneo Pharmaceuticals, Inc. | -77.38 Million USD | -42.863% |
| Xencor, Inc. | -126.08 Million USD | 12.315% |
| 60 Degrees Pharmaceuticals, Inc. | -3.76 Million USD | -2835.947% |
| Replimune Group, Inc. | -215.79 Million USD | 48.766% |
| Coeptis Therapeutics Holdings, Inc. | -21.26 Million USD | -419.873% |
| Vanda Pharmaceuticals Inc. | 2.5 Million USD | 4506.497% |
| Lexaria Bioscience Corp. | -6.66 Million USD | -1558.825% |
| Portage Biotech Inc. | -75.33 Million USD | -46.749% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | -1219.818% |
| Olema Pharmaceuticals, Inc. | -96.65 Million USD | -14.385% |
| OncoCyte Corporation | -27.78 Million USD | -297.966% |
| Qualigen Therapeutics, Inc. | -13.41 Million USD | -724.009% |
| Processa Pharmaceuticals, Inc. | -11.12 Million USD | -894.1% |
| Purple Biotech Ltd. | -19.88 Million USD | -456.132% |
| CollPlant Biotechnologies Ltd. | -7.01 Million USD | -1475.139% |
| scPharmaceuticals Inc. | -54.81 Million USD | -101.713% |
| ProMIS Neurosciences, Inc. | -17.5 Million USD | -531.544% |
| HilleVax, Inc. | -123.56 Million USD | 10.526% |
| NeuroSense Therapeutics Ltd. | -10.1 Million USD | -993.885% |
| Tharimmune, Inc. | -9.31 Million USD | -1086.371% |
| Genprex, Inc. | -30.86 Million USD | -258.255% |
| Neumora Therapeutics, Inc. Common Stock | -235.92 Million USD | 53.138% |
| Atossa Therapeutics, Inc. | -30.09 Million USD | -267.379% |
| XTL Biopharmaceuticals Ltd. | -1.78 Million USD | -6104.209% |
| Virios Therapeutics, Inc. | -5.29 Million USD | -1987.588% |
| OKYO Pharma Limited | -16.82 Thousand USD | -656993.476% |
| Savara Inc. | -54.69 Million USD | -102.126% |
| Curis, Inc. | -47.41 Million USD | -133.183% |
| Daré Bioscience, Inc. | -30.16 Million USD | -266.558% |
| Carmell Therapeutics Corporation | -15.44 Million USD | -615.82% |
| Titan Pharmaceuticals, Inc. | -5.56 Million USD | -1885.258% |
| Achieve Life Sciences, Inc. | -29.81 Million USD | -270.817% |
| BeiGene, Ltd. | -881.7 Million USD | 87.461% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | -419.203% |
| Revolution Medicines, Inc. Warrant | -436.36 Million USD | 74.664% |
| Protagonist Therapeutics, Inc. | -78.95 Million USD | -40.028% |
| Erasca, Inc. | -125.04 Million USD | 11.583% |
| bluebird bio, Inc. | -211.91 Million USD | 47.828% |
| Protagenic Therapeutics, Inc. | -5 Million USD | -2110.96% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 165.948% |
| DBV Technologies S.A. | -72.72 Million USD | -52.021% |
| Protagenic Therapeutics, Inc. | -5 Million USD | -2110.96% |
| Moderna, Inc. | -4.71 Billion USD | 97.655% |
| Vincerx Pharma, Inc. | -40.15 Million USD | -175.317% |
| Fresh Tracks Therapeutics, Inc. | -5.69 Million USD | -1841.675% |
| Molecular Templates, Inc. | -8.12 Million USD | -1260.894% |
| Acrivon Therapeutics, Inc. Common Stock | -60.38 Million USD | -83.081% |
| Travere Therapeutics, Inc. | -111.39 Million USD | 0.754% |
| Monte Rosa Therapeutics, Inc. | -135.35 Million USD | 18.317% |
| Spruce Biosciences, Inc. | -47.91 Million USD | -130.721% |
| Celldex Therapeutics, Inc. | -141.42 Million USD | 21.827% |
| Cogent Biosciences, Inc. | -192.41 Million USD | 42.54% |
| MacroGenics, Inc. | -9.05 Million USD | -1120.567% |
| RenovoRx, Inc. | -10.23 Million USD | -980.522% |
| Adicet Bio, Inc. | -142.65 Million USD | 22.501% |
| Prime Medicine, Inc. | -198.13 Million USD | 44.2% |
| Aditxt, Inc. | -32.38 Million USD | -241.433% |
| Adagene Inc. | -18.94 Million USD | -483.537% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -1412.079% |
| Quantum-Si incorporated | -95.96 Million USD | -15.214% |
| Maravai LifeSciences Holdings, Inc. | -119.02 Million USD | 7.116% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | -658.408% |
| Voyager Therapeutics, Inc. | 132.33 Million USD | 183.548% |
| SciSparc Ltd. | -5.12 Million USD | -2058.512% |
| Vericel Corporation | -3.18 Million USD | -3374.513% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | -91837.898% |
| Minerva Neurosciences, Inc. | -30 Million USD | -268.464% |
| Generation Bio Co. | -126.61 Million USD | 12.679% |
| Astria Therapeutics, Inc. | -72.89 Million USD | -51.677% |
| Black Diamond Therapeutics, Inc. | -82.44 Million USD | -34.105% |
| Arcutis Biotherapeutics, Inc. | -262.14 Million USD | 57.824% |
| Invivyd, Inc. | -198.64 Million USD | 44.343% |
| Relay Therapeutics, Inc. | -341.97 Million USD | 67.67% |
| Quoin Pharmaceuticals, Ltd. | -8.68 Million USD | -1172.757% |
| Spero Therapeutics, Inc. | 22.8 Million USD | 584.78% |
| Artelo Biosciences, Inc. | -9.87 Million USD | -1019.698% |
| 2seventy bio, Inc. | -217.57 Million USD | 49.185% |
| ADMA Biologics, Inc. | -28.23 Million USD | -291.512% |
| Clene Inc. | -49.5 Million USD | -123.333% |
| Capricor Therapeutics, Inc. | -22.28 Million USD | -396.057% |
| Boundless Bio, Inc. Common Stock | -49.43 Million USD | -123.65% |
| GeoVax Labs, Inc. | -25.96 Million USD | -325.771% |
| Recursion Pharmaceuticals, Inc. | -328.06 Million USD | 66.3% |
| Citius Pharmaceuticals, Inc. | -32.54 Million USD | -239.733% |
| Contineum Therapeutics, Inc. Class A Common Stock | 22.72 Million USD | 586.615% |
| Relmada Therapeutics, Inc. | -98.79 Million USD | -11.911% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | -47.897% |
| ALX Oncology Holdings Inc. | -160.8 Million USD | 31.247% |
| Vir Biotechnology, Inc. | -615.06 Million USD | 82.025% |
| Evaxion Biotech A/S | -22.12 Million USD | -399.702% |
| Ocular Therapeutix, Inc. | -80.73 Million USD | -36.939% |
| Verve Therapeutics, Inc. | -200.06 Million USD | 44.739% |
| Trevena, Inc. | -40.28 Million USD | -174.415% |
| Surrozen, Inc. | -43.04 Million USD | -156.863% |
| Tyra Biosciences, Inc. | -69.13 Million USD | -59.92% |
| Cingulate Inc. | -23.53 Million USD | -369.765% |
| Galmed Pharmaceuticals Ltd. | -6.91 Million USD | -1499.523% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -177.368% |
| Tenax Therapeutics, Inc. | -7.71 Million USD | -1333.844% |
| Terns Pharmaceuticals, Inc. | -90.21 Million USD | -22.557% |
| ACADIA Pharmaceuticals Inc. | -61.28 Million USD | -80.398% |
| Connect Biopharma Holdings Limited | -59.5 Million USD | -85.804% |
| Clearmind Medicine Inc. | -11.95 Million USD | -824.791% |
| Kronos Bio, Inc. | -112.67 Million USD | 1.876% |
| Bolt Biotherapeutics, Inc. | -69.19 Million USD | -59.774% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | -4359086.667% |
| Viking Therapeutics, Inc. | -85.89 Million USD | -28.714% |
| Statera Biopharma, Inc. | -174.4 Million USD | 36.609% |
| ImmunityBio, Inc. | -583.19 Million USD | 81.043% |
| Korro Bio, Inc. | -81.17 Million USD | -36.203% |
| Kineta, Inc. | -14.09 Million USD | -684.162% |
| BioVie Inc. | -32.12 Million USD | -244.2% |
| Codexis, Inc. | -76.24 Million USD | -45.014% |
| Celularity Inc. | -196.29 Million USD | 43.677% |
| Crinetics Pharmaceuticals, Inc. | -214.52 Million USD | 48.464% |
| Celcuity Inc. | -63.77 Million USD | -73.347% |
| Virax Biolabs Group Limited | -6.73 Million USD | -1541.916% |
| Cibus, Inc. | -267.62 Million USD | 58.689% |
| Eledon Pharmaceuticals, Inc. | -40.32 Million USD | -174.163% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | -208.729% |
| IN8bio, Inc. | -30 Million USD | -268.444% |
| Kodiak Sciences Inc. | -260.49 Million USD | 57.557% |
| Annexon, Inc. | -134.23 Million USD | 17.639% |
| Adverum Biotechnologies, Inc. | -117.16 Million USD | 5.638% |
| Assembly Biosciences, Inc. | -61.22 Million USD | -80.569% |
| Avalo Therapeutics, Inc. | -31.54 Million USD | -250.491% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 69.816% |
| Eyenovia, Inc. | -27.26 Million USD | -305.556% |
| Puma Biotechnology, Inc. | 21.59 Million USD | 612.061% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | -20565.234% |
| Xilio Therapeutics, Inc. | -76.4 Million USD | -44.703% |
| Arcellx, Inc. | -70.69 Million USD | -56.4% |
| Cardiff Oncology, Inc. | -41.44 Million USD | -166.787% |
| Enanta Pharmaceuticals, Inc. | -133.81 Million USD | 17.38% |
| Regulus Therapeutics Inc. | -30.03 Million USD | -268.076% |
| Moolec Science SA | -51.78 Million USD | -113.48% |
| Acumen Pharmaceuticals, Inc. | -52.37 Million USD | -111.107% |
| Geron Corporation | -184.12 Million USD | 39.955% |
| LAVA Therapeutics N.V. | -41.97 Million USD | -163.399% |
| Royalty Pharma plc | 1.13 Billion USD | 109.742% |
| Atea Pharmaceuticals, Inc. | -135.95 Million USD | 18.68% |
| Greenwich LifeSciences, Inc. | -8.89 Million USD | -1143.381% |
| TFF Pharmaceuticals, Inc. | -21.24 Million USD | -420.443% |
| Mersana Therapeutics, Inc. | -171.67 Million USD | 35.598% |
| Humacyte, Inc. | -110.77 Million USD | 0.196% |
| Structure Therapeutics Inc. | -89.62 Million USD | -23.364% |
| 89bio, Inc. | -142.18 Million USD | 22.245% |
| PMV Pharmaceuticals, Inc. | -68.96 Million USD | -60.323% |
| Avenue Therapeutics, Inc. | -10.37 Million USD | -965.424% |
| Genelux Corporation | -28.29 Million USD | -290.709% |
| Trevi Therapeutics, Inc. | -29.06 Million USD | -280.385% |
| Lexicon Pharmaceuticals, Inc. | -177.11 Million USD | 37.579% |
| Notable Labs, Ltd. | -11.26 Million USD | -881.525% |
| Liquidia Corporation | -78.5 Million USD | -40.836% |
| Mustang Bio, Inc. | -51.6 Million USD | -114.253% |
| Immunovant, Inc. | -259.33 Million USD | 57.368% |
| Quantum-Si incorporated | -95.96 Million USD | -15.214% |
| Arbutus Biopharma Corporation | -72.84 Million USD | -51.765% |
| DiaMedica Therapeutics Inc. | -19.38 Million USD | -470.45% |
| Vera Therapeutics, Inc. | -95.99 Million USD | -15.178% |
| Acasti Pharma Inc. | -12.85 Million USD | -760.181% |
| MiNK Therapeutics, Inc. | -22.45 Million USD | -392.295% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | -592.654% |
| Xenon Pharmaceuticals Inc. | -182.39 Million USD | 39.384% |
| Elevai Labs, Inc. Common Stock | -4.3 Million USD | -2470.233% |
| NeuroBo Pharmaceuticals, Inc. | -12.47 Million USD | -786.6% |
| Tempest Therapeutics, Inc. | -29.49 Million USD | -274.891% |
| Soleno Therapeutics, Inc. | -38.98 Million USD | -183.572% |
| PepGen Inc. | -78.62 Million USD | -40.614% |
| Moleculin Biotech, Inc. | -29.76 Million USD | -271.39% |
| United Therapeutics Corporation | 984.8 Million USD | 111.227% |
| Nuvectis Pharma, Inc. | -22.26 Million USD | -396.671% |
| Solid Biosciences Inc. | -96.01 Million USD | -15.148% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -2207.415% |
| Immuneering Corporation | -53.47 Million USD | -106.762% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | -2073.351% |
| Silo Pharma, Inc. | -3.7 Million USD | -2887.53% |
| Belite Bio, Inc | -31.63 Million USD | -249.516% |
| XOMA Corporation | -40.83 Million USD | -170.772% |
| ARS Pharmaceuticals, Inc. | -54.36 Million USD | -103.364% |
| Bionomics Limited | -15.49 Billion USD | 99.286% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | -31.641% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | -279.185% |
| uniQure N.V. | -308.47 Million USD | 64.16% |
| Cassava Sciences, Inc. | -97.21 Million USD | -13.724% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -1412.079% |
| Poseida Therapeutics, Inc. | -123.43 Million USD | 10.428% |
| Forte Biosciences, Inc. | -31.47 Million USD | -251.249% |
| Anebulo Pharmaceuticals, Inc. | -8.2 Million USD | -1248.001% |
| Enlivex Therapeutics Ltd. | -29.06 Million USD | -280.346% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | -20565.234% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | -321.466% |
| FibroBiologics, Inc. Common Stock | -16.48 Million USD | -570.664% |
| Altimmune, Inc. | -88.44 Million USD | -25.0% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 27.064% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | -279.185% |
| Compugen Ltd. | -18.75 Million USD | -489.522% |
| Peak Bio, Inc. | -1259.26 USD | -8779580.13% |
| Zevra Therapeutics, Inc. | -46.04 Million USD | -140.09% |
| Benitec Biopharma Inc. | -21.75 Million USD | -408.294% |
| Spyre Therapeutics, Inc. | -338.79 Million USD | 67.367% |
| NKGen Biotech, Inc. Common Stock | -82.95 Million USD | -33.277% |
| Zura Bio Limited | -60.36 Million USD | -83.166% |
| PolyPid Ltd. | -23.86 Million USD | -363.268% |
| Aileron Therapeutics, Inc. | -15.73 Million USD | -602.765% |
| NKGen Biotech, Inc. Warrants | -82.95 Million USD | -33.277% |
| Instil Bio, Inc. | -156.08 Million USD | 29.168% |
| argenx SE | -295.05 Million USD | 62.529% |
| Immunome, Inc. | -106.8 Million USD | -3.514% |
| Compass Therapeutics, Inc. | -42.49 Million USD | -160.176% |
| Verona Pharma plc | -54.36 Million USD | -103.349% |
| enGene Holdings Inc. Warrants | -99.91 Million USD | -10.651% |
| Shattuck Labs, Inc. | -87.29 Million USD | -26.646% |
| CervoMed Inc. | -2.17 Million USD | -4990.491% |
| LENZ Therapeutics, Inc. | -124.65 Million USD | 11.305% |
| Plus Therapeutics, Inc. | -13.31 Million USD | -730.272% |
| Dianthus Therapeutics, Inc. | -43.55 Million USD | -153.838% |
| Moolec Science SA | -51.78 Million USD | -113.48% |
| Enveric Biosciences, Inc. | -17.29 Thousand USD | -639275.008% |
| Inovio Pharmaceuticals, Inc. | -135.11 Million USD | 18.176% |
| AnaptysBio, Inc. | -163.61 Million USD | 32.429% |
| Design Therapeutics, Inc. | -66.86 Million USD | -65.354% |
| Leap Therapeutics, Inc. | -81.41 Million USD | -35.799% |
| NeurAxis, Inc. | -14.62 Million USD | -655.872% |
| Seelos Therapeutics, Inc. | -37.88 Million USD | -191.851% |
| Lumos Pharma, Inc. | -34.03 Million USD | -224.849% |
| Achilles Therapeutics plc | -69.66 Million USD | -58.701% |
| enGene Holdings Inc. Common Stock | -99.91 Million USD | -10.651% |
| 180 Life Sciences Corp. | -19.93 Million USD | -454.594% |
| Opiant Pharmaceuticals, Inc. | 3 Million USD | 3774.534% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | -4359086.667% |
| Nutriband Inc. | -5.48 Million USD | -1915.546% |
| ORIC Pharmaceuticals, Inc. | -100.69 Million USD | -9.794% |
| CG Oncology, Inc. Common stock | -48.6 Million USD | -127.455% |
| Fractyl Health, Inc. Common Stock | -77.09 Million USD | -43.414% |
| Rani Therapeutics Holdings, Inc. | -33.97 Million USD | -225.461% |
| MoonLake Immunotherapeutics | -36 Million USD | -207.046% |
| Palisade Bio, Inc. | -12.3 Million USD | -798.854% |
| Tourmaline Bio, Inc. | -42.12 Million USD | -162.461% |
| Beam Therapeutics Inc. | -132.52 Million USD | 16.576% |
| Neurogene Inc. | -36.31 Million USD | -204.428% |
| Mirum Pharmaceuticals, Inc. | -163.41 Million USD | 32.345% |
| AEON Biopharma, Inc. | -52.55 Million USD | -110.364% |
| CARGO Therapeutics, Inc. Common Stock | -98.14 Million USD | -12.646% |
| Sesen Bio, Inc. | -19.88 Million USD | -456.02% |
| Enliven Therapeutics, Inc. | -71.58 Million USD | -54.447% |
| Kiora Pharmaceuticals, Inc. | -12.51 Million USD | -783.49% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 75.101% |
| Taysha Gene Therapies, Inc. | -111.56 Million USD | 0.903% |
| Athira Pharma, Inc. | -117.67 Million USD | 6.045% |
| Vaccinex, Inc. | -20.25 Million USD | -445.943% |
| HCW Biologics Inc. | -24.99 Million USD | -342.337% |
| XOMA Corporation | -40.83 Million USD | -170.772% |
| Nektar Therapeutics | -276.05 Million USD | 59.951% |
| Arvinas, Inc. | -367.3 Million USD | 69.9% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | -164116.859% |
| Merus N.V. | -154.93 Million USD | 28.644% |
| Omega Therapeutics, Inc. | -97.42 Million USD | -13.478% |
| Quince Therapeutics, Inc. | -31.38 Million USD | -252.267% |
| Rezolute, Inc. | -68.45 Million USD | -61.497% |
| Clene Inc. | -49.5 Million USD | -123.333% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | -616.823% |
| BeyondSpring Inc. | -21.02 Million USD | -425.82% |
| Synlogic, Inc. | -57.28 Million USD | -93.008% |
| Allarity Therapeutics, Inc. | -11.9 Million USD | -828.989% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | -921.236% |
| Peak Bio, Inc. | -1259.26 USD | -8779580.13% |
| Werewolf Therapeutics, Inc. | -37.36 Million USD | -195.865% |
| Krystal Biotech, Inc. | 10.93 Million USD | 1111.334% |
| Karyopharm Therapeutics Inc. | -143.09 Million USD | 22.74% |
| SpringWorks Therapeutics, Inc. | -325.1 Million USD | 65.993% |
| Lipella Pharmaceuticals Inc. | -4.61 Million USD | -2293.588% |
| MannKind Corporation | -11.93 Million USD | -826.11% |
| Ikena Oncology, Inc. | -68.16 Million USD | -62.191% |
| Cyclerion Therapeutics, Inc. | -21.01 Million USD | -426.096% |
| Gyre Therapeutics, Inc. | -92.93 Million USD | -18.966% |
| Gossamer Bio, Inc. | -179.81 Million USD | 38.516% |
| CohBar, Inc. | -11.96 Million USD | -824.243% |
| Cognition Therapeutics, Inc. | -25.78 Million USD | -328.723% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | -266.697% |
| Legend Biotech Corporation | -518.25 Million USD | 78.667% |
| Mural Oncology plc | -207.44 Million USD | 46.705% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 10.922% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | -504.487% |
| Disc Medicine, Inc. | -76.42 Million USD | -44.656% |
| Champions Oncology, Inc. | -7.27 Million USD | -1419.502% |
| REGENXBIO Inc. | -263.49 Million USD | 58.041% |
| Ensysce Biosciences, Inc. | -10.61 Million USD | -941.725% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -132.731% |
| Cellectar Biosciences, Inc. | -37.98 Million USD | -191.071% |
| Edgewise Therapeutics, Inc. | -100.16 Million USD | -10.379% |
| Vaxart, Inc. | -82.46 Million USD | -34.068% |
| PharmaCyte Biotech, Inc. | 333.76 Thousand USD | 33225.002% |
| Aldeyra Therapeutics, Inc. | -37.54 Million USD | -194.49% |
| Cellectis S.A. | -101.05 Million USD | -9.4% |
| Longeveron Inc. | -21.41 Million USD | -416.317% |
| Repare Therapeutics Inc. | -93.79 Million USD | -17.872% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 79.372% |
| Inozyme Pharma, Inc. | -71.16 Million USD | -55.347% |
| Revolution Medicines, Inc. | -436.36 Million USD | 74.664% |
| Nymox Pharmaceutical Corporation | -6.57 Million USD | -1582.529% |
| Third Harmonic Bio, Inc. | -30.82 Million USD | -258.678% |
| ArriVent BioPharma, Inc. Common Stock | -69.33 Million USD | -59.461% |
| AN2 Therapeutics, Inc. | -64.73 Million USD | -70.795% |
| Anixa Biosciences, Inc. | -9.81 Million USD | -1026.888% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 103.054% |
| Denali Therapeutics Inc. | -145.22 Million USD | 23.87% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | -91837.898% |
| Veru Inc. | -93.15 Million USD | -18.686% |
| Corvus Pharmaceuticals, Inc. | -27.02 Million USD | -309.038% |
| Cingulate Inc. | -23.53 Million USD | -369.765% |
| Passage Bio, Inc. | -102.06 Million USD | -8.325% |
| Context Therapeutics Inc. | -23.96 Million USD | -361.35% |
| Exicure, Inc. | -16.91 Million USD | -553.654% |
| Day One Biopharmaceuticals, Inc. | -188.91 Million USD | 41.477% |
| Oramed Pharmaceuticals Inc. | -37.76 Million USD | -192.763% |
| Scinai Immunotherapeutics Ltd. | -6.5 Million USD | -1598.993% |
| Rhythm Pharmaceuticals, Inc. | -184.67 Million USD | 40.134% |
| Nuvalent, Inc. | -126.21 Million USD | 12.407% |
| ABVC BioPharma, Inc. | -10.51 Million USD | -951.375% |
| Carisma Therapeutics, Inc. | -86.87 Million USD | -27.256% |
| Unicycive Therapeutics, Inc. | -30.54 Million USD | -261.966% |
| OmniAb, Inc. | -50.61 Million USD | -118.414% |
| Anew Medical, Inc. | 1.34 Million USD | 8313.13% |
| Fennec Pharmaceuticals Inc. | -16.04 Million USD | -589.056% |
| Lipocine Inc. | -16.35 Million USD | -576.116% |
| Lexeo Therapeutics, Inc. Common Stock | -66.39 Million USD | -66.52% |
| Nautilus Biotechnology, Inc. | -63.67 Million USD | -73.63% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | -162.027% |
| G1 Therapeutics, Inc. | -47.96 Million USD | -130.49% |
| Bellerophon Therapeutics, Inc. | -19.83 Million USD | -457.506% |
| Sage Therapeutics, Inc. | -541.48 Million USD | 79.582% |
| Ocugen, Inc. | -63.07 Million USD | -75.273% |
| Mind Medicine (MindMed) Inc. | -95.73 Million USD | -15.488% |
| Q32 Bio Inc. | -112.96 Million USD | 2.126% |
| Brainstorm Cell Therapeutics Inc. | -17.19 Million USD | -543.084% |
| Alumis Inc. Common Stock | -154.99 Million USD | 28.668% |
| Equillium, Inc. | -13.33 Million USD | -729.089% |
| Kyverna Therapeutics, Inc. | -60.36 Million USD | -83.148% |
| Coya Therapeutics, Inc. | -7.98 Million USD | -1284.092% |
| CNS Pharmaceuticals, Inc. | -18.85 Million USD | -486.482% |
| Galera Therapeutics, Inc. | -59.08 Million USD | -87.128% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 3.465% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | -501.585% |
| Dominari Holdings Inc. | -22.88 Million USD | -383.17% |
| Edesa Biotech, Inc. | -8.37 Million USD | -1220.2% |
| vTv Therapeutics Inc. | -20.25 Million USD | -445.97% |
| Bio-Techne Corporation | 168.1 Million USD | 165.768% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 68.599% |
| Harmony Biosciences Holdings, Inc. | 128.85 Million USD | 185.802% |
| Prelude Therapeutics Incorporated | -121.83 Million USD | 9.253% |
| Candel Therapeutics, Inc. | -37.93 Million USD | -191.413% |
| iTeos Therapeutics, Inc. | -112.64 Million USD | 1.849% |
| Nkarta, Inc. | -117.5 Million USD | 5.908% |
| BioCardia, Inc. | -11.57 Million USD | -855.484% |
| Iterum Therapeutics plc | -38.37 Million USD | -188.132% |